Developing a new treatment for pulmonary hypertension
Official title: Preclinical Development of a Novel eNAMPT-Neutralizing mAb for Pulmonary Hypertension
Funded at Aqualung Therapeutics Corp. · NIH-10931660 · Data updated 2026-11-12
This study is testing a new treatment for pulmonary arterial hypertension (PAH) that uses a special antibody to block a protein linked to heart and lung problems, with the hope of helping patients feel better and live longer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Aqualung Therapeutics Corp. NIH-funded |
| Lab location | 1 site (Juno Beach, UNITED STATES) |
| Project start | September 1, 2022 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $808,999 |
| NIH project number | 5R42HL164300-03 |
| Project ID | NIH-10931660 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with pulmonary arterial hypertension who are experiencing right ventricular dysfunction.
✕Less likely to help
Patients with pulmonary hypertension caused by factors unrelated to eNAMPT or those with other severe comorbidities may not benefit from this research.
What this research studies
This research focuses on a novel therapy targeting pulmonary arterial hypertension (PAH), a serious condition that affects the lungs and heart. The approach involves a humanized monoclonal antibody designed to neutralize a specific protein called eNAMPT, which is linked to inflammation and worsening heart function in PAH patients. By blocking this protein, the research aims to improve right ventricular function and overall survival in individuals suffering from this disease. The study will utilize preclinical models to evaluate the effectiveness and safety of this new treatment.
Why it matters
Potential benefit: If successful, this research could lead to a new therapy that significantly improves outcomes for patients with pulmonary hypertension.
How similar studies have gone: Previous research has indicated that targeting inflammatory pathways in pulmonary hypertension can be effective, suggesting potential success for this novel approach.
Where this research is happening
-
Aqualung Therapeutics Corp.
Juno Beach, United States Active
Researchers
- Principal investigator: Garcia, Joe G. N. — Aqualung Therapeutics Corp.
- Study coordinator: Garcia, Joe G. N.
Related research
Other NIH-funded projects on the same topics.
-
Understanding how CD4 T cells fuel schistosomiasis-related lung disease
A study explores how specific immune cells and inflammatory signals in schistosomiasis may contribute to pulmonary hypertension in people affected by the disease.
-
CD4 T Cells, Schistosoma, and Pulmonary Hypertension: Understanding How Immune Cells Drive Disease
A human-health focused study uses a mouse model and human samples to explore how immune cells and inflammation may contribute to a lung blood vessel disease linked to schistosomiasis.
-
CD4 T Cells and Schistosoma-Related Pulmonary Hypertension
A study to understand how specific immune cells behave in a lung complication caused by schistosomiasis, with the goal of finding targets to prevent or treat it.
-
Clinical CT Imaging to identify and subtype pulmonary hypertension in COPD
A new CT imaging approach aims to help doctors detect and classify pulmonary hypertension in people with COPD.
-
Right heart remodeling in pulmonary hypertension
In people with pulmonary hypertension, researchers are studying how the right side of the heart changes and why it fails, with the goal of finding new treatments.
-
TEMPO-PH: How the right heart adapts in pulmonary hypertension over time
A study to build a detailed molecular portrait of why the right side of the heart fails in pulmonary hypertension and how a common heart medicine might help.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.